Lawyers to meet next week on Merck's Vioxx - NYT

Key points
- Drugs giant Merck & Co. which pulled its blockbuster painkiller Vioxx from shelves in September, is about to become the target of hundreds of plaintiffs' lawyers, the New York Times reported on Friday.
- The report said that the attorneys, representing people who claim injury or death because of the use of Vioxx, plan to meet next week to lay the foundations for a nationwide blitz against Merck.
- Merck has been buffeted since the company pulled Vioxx after it was shown to increase the risk of heart attack and strokes.
- The Times said lawyers expect the discussions to begin informally on Tuesday in Pasadena, Calif., in the hallways of a conference on Vioxx litigation that will also be open to defense lawyers.
Drugs giant Merck & Co. which pulled its blockbuster painkiller Vioxx from shelves in September, is about to become the target of hundreds of plaintiffs' lawyers, the New York Times reported on Friday.
The report said that the attorneys, representing people who claim injury or death because of the use of Vioxx, plan to meet next week to lay the foundations for a nationwide blitz against Merck.
Merck has been buffeted since the company pulled Vioxx after it was shown to increase the risk of heart attack and strokes.
The Times said lawyers expect the discussions to begin informally on Tuesday in Pasadena, Calif., in the hallways of a conference on Vioxx litigation that will also be open to defense lawyers.
On Thursday, at a meeting in Las Vegas, only lawyers of those who are suing Merck, or plan to, expect to discuss specific strategies, the report added.
Reserve, Louisiana-based Daniel E. Becnel Jr. told the newspaper that the Vioxx case "needs to be managed by the premier lawyers in the country."
The specter of litigation against Merck has increased since the recall was issued in late September.
On Thursday, Swiss scientists writing in a report for British medical journal The Lancet said that the company should have pulled Vioxx four years ago because of data showing an elevated risk of a cardiovascular event.
But Merck disputed the idea it knew of the COX-2 inhibitor's problems that far in advance. Vioxx has been taken by an estimated 20 million Americans since its launch in 1999.
Written and revised by
Andrey Nailor, M.D.
Our doctors write and review articles for accuracy and keep them up to date.
health.am provides general information, not medical advice. Always consult a qualified health professional about your own health.
Explore health topics
More in this topic
Addiction →
NewsCan marijuanna help transplant patients?
Here's another discovery to bolster the case for medical marijuana: New research in mice suggests that THC, the active ingredient in marijuana, may delay the rejection of incompatible organs. Although more research is…
2 September 2015
NewsSomething to chew on - millions of lives blighted by smokeless tobacco
More than a quarter of a million people die each year from using smokeless tobacco, researchers at the University of York have concluded. Millions more have their lives shortened by ill health due to the effects of…
22 August 2015
NewsTeen marijuana use not linked to later depression, lung cancer, other health problems, study finds
Chronic marijuana use by teenage boys does not appear to be linked to later physical or mental health issues such as depression, psychotic symptoms or asthma, according to a study published by the American Psychological…